<DOC>
	<DOCNO>NCT02085538</DOCNO>
	<brief_summary>Since amount palbociclib eliminate urine 6.9 % , renal impairment expect much impact palbociclib . However , Federal Drug Administration ( FDA ) Guidance recommend study subject renal impairment drug likely use patient impaired renal function . Palbociclib intend chronic use cancer patient may degree impaired renal function .</brief_summary>
	<brief_title>Study Of Palbociclib ( PD-0332991 ) In Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<criteria>Personally sign date informed consent document . Renal function calculate Cockcroft Gault equation : normal function ( CLcr &gt; =90 mL/min ) , mild : CLcr &gt; =60 mL/min &lt; 90 mL/min , moderate : CLcr &gt; =30 mL/min &lt; 60 mL/min , severe : CLcr &lt; 30 mL/min require hemodialysis . Subjects normal renal function match age , weight , gender race subject impair renal function group . Any condition possibly affect drug absorption . Renal allograft recipient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>renal impairment</keyword>
	<keyword>AUC</keyword>
	<keyword>Cmax</keyword>
	<keyword>palbociclib</keyword>
	<keyword>normal match subject</keyword>
</DOC>